Table 3.
Results of antimicrobial resistance of Bacillus cereus isolates in the study.
| Category | Antimicrobial agents |
Bacillus cereus (n = 103) |
||
|---|---|---|---|---|
| Sensitive | Intermediate | Resistant | ||
| I | β-Lactams | |||
| Ampicillin (10 μg) | 1 (1%) | 0 (0%) | 102 (99%) | |
| Amoxicillin-clavulanic acid (20 μg/10 μg) | 6 (6%) | 30 (29%) | 67 (65%) | |
| Penicillin (10 units) | 1 (1%) | 0 (0%) | 102 (99%) | |
| Cephalothin (30 μg) | 9 (9%) | 23 (22%) | 71 (69%) | |
| Cefoxitin (30 μg) | 5 (5%) | 0 (0%) | 98 (95%) | |
| Cefotetan (30 μg) | 76 (74%) | 15 (15%) | 12 (12%) | |
| II | Carbapenems | |||
| Imipenem (10 μg) | 103 (100%) | 0 (0%) | 0 (0%) | |
| III | Aminoglycosides | |||
| Gentamicin (10 μg) | 103 (100%) | 0 (0%) | 0 (0%) | |
| Kanamycin (30 μg) | 88 (85%) | 15 (15%) | 0 (0%) | |
| IV | Macrolides | |||
| Erythromycin (15 μg) | 83 (81%) | 19 (18%) | 1 (1%) | |
| Telithromycin (15 μg) | 89 (86%) | 11 (11%) | 3 (3%) | |
| V | Glycopeptides | |||
| Vancomycin (30 μg) | 90 (87 %) | – | – | |
| Teicoplanin (30 μg) | 88 (85%) | 14 (14%) | 1 (1%) | |
| VI | Quinolones | |||
| Ciprofloxacin (5 μg) | 99 (96%) | 4 (4%) | 0 (0%) | |
| VII | Amphenicols | |||
| Chloramphenicol (30 μg) | 103 (100%) | 0 (0%) | 0 (0%) | |
| VIII | Tetracyclines | |||
| Tetracycline (30 μg) | 86 (84%) | 8 (8%) | 9 (9%) | |
| IX | Folic acid inhibitors | |||
| Trimethoprim-Sulfamethoxazole (1.25μg/23.75 μg) | 83 (81%) | 9 (9%) | 11 (11%) | |
| X | Lincosamides | |||
| Clindamycin (2 μg) | 8 (8%) | 91 (88%) | 4 (4%) | |
| The others | Rifampin (5 μg) | 0 (0%) | 3 (3%) | 100 (97%) |
| Quinupristin (15 μg) | 14 (14%) | 75 (73%) | 14 (14%) | |
| Nitrofurantoin (300 μg) | 42 (41%) | 53 (52%) | 8 (8%) | |
| Pansusceptible | ||||
| ≥3 Antimicrobia | 34% | |||
| ≥4 Antimicrobia | 11% | |||
| ≥5 Antimicrobia | 4% | |||